Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Stock Short Interest Report for October

Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Get Free Report) saw a large growth in short interest in October. As of October 30th, there was short interest totaling 12,377 shares, a growth of 92.5% from the October 15th total of 6,429 shares. Based on an average daily volume of 37,998 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the company’s shares are short sold.

Neuphoria Therapeutics Trading Down 1.2%

NASDAQ NEUP traded down $0.03 on Friday, hitting $2.55. The company’s stock had a trading volume of 14,972 shares, compared to its average volume of 36,892. The firm has a market cap of $13.80 million, a P/E ratio of -0.41 and a beta of 0.77. Neuphoria Therapeutics has a 52-week low of $2.49 and a 52-week high of $5.53. The company’s 50-day simple moving average is $3.37 and its 200 day simple moving average is $4.09.

Wall Street Analyst Weigh In

Several research firms have weighed in on NEUP. Wall Street Zen raised shares of Neuphoria Therapeutics to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, August 27th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $7.00.

View Our Latest Report on Neuphoria Therapeutics

Institutional Trading of Neuphoria Therapeutics

A hedge fund recently bought a new stake in Neuphoria Therapeutics stock. ADAR1 Capital Management LLC acquired a new position in Neuphoria Therapeutics Inc. (NASDAQ:NEUP – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 30,000 shares of the company’s stock, valued at approximately $131,000. ADAR1 Capital Management LLC owned approximately 0.56% of Neuphoria Therapeutics at the end of the most recent quarter. 15.90% of the stock is owned by institutional investors.

About Neuphoria Therapeutics

(Get Free Report)

Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

See Also

Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.